Immunization, Insurance and White Paper - Pharmacy Technician Pulse

UK enacts law to decentralise manufacture of personalised treatments

Pharmaceutical Technology

JULY 23, 2025

The legislation also supports the use of mobile manufacturing units, offering close-to-home treatment for patients too unwell to travel, or whose weakened immune systems mean hospital visits carry extra risk. Give your business an edge with our leading industry insights.

Communication

Communication Hospitals Packaging Insurance

Bharat Biotech acquires licence for GSK’s Shigella vaccine development

Pharmaceutical Technology

JUNE 13, 2025

The technology utilises outer membrane vesicles (OMVs) to deliver antigens, often eliminating the need for adjuvants while triggering the immune response. Discovered and developed by GSK’s global health team scientists, the GMMA technology is a low-cost platform ideal for creating vaccines in resource-limited settings.

Vaccines

Vaccines Communication Hospitals Packaging

MetrioPharm gains orphan drug status from EMA for MP1032

Pharmaceutical Technology

JULY 30, 2025

“MP1032’s unique mechanism — modulating mitochondrial ROS in overactive immune cells — could transform long-term DMD management by slashing corticosteroid doses and side effects. Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

Packaging

Packaging Communication Immunization FDA

EC approves argenx’s efgartigimod alfa for CIDP treatment

Pharmaceutical Technology

JUNE 23, 2025

The European Commission (EC) has approved argenx’s Vyvgart (efgartigimod alfa) 1000mg as a single agent for subcutaneous injection to treat adults with chronic inflammatory demyelinating polyneuropathy (CIDP), an immune-mediated neuromuscular disorder of the peripheral nervous system.

Communication

Communication Hospitals Packaging Insurance

Juvenescence enhances AI drug discovery with Ro5 acquisition

Pharmaceutical Technology

JUNE 6, 2025

This integration will reinforce Juvenescence’s pipeline in cardio-metabolism, cognition, immunity and cellular repair sectors. Incorporating Ro5’s AI platform into Juvenescence is expected to accelerate the development of AI-enabled treatments. Give your business an edge with our leading industry insights.

Communication

Communication Hospitals Packaging Compounding

J&J seeks FDA approval for icotrokinra to treat psoriasis

Pharmaceutical Technology

JULY 22, 2025

July 22, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook PsO is an immune-mediated disease characterised by rapid skin cell proliferation leading to inflamed plaques that can cause discomfort or pain. Credit: design_cam/Shutterstock.com. Give your business an edge with our leading industry insights.

FDA

FDA Immunization Packaging Communication

Harbour BioMed partners Otsuka on new T-cell therapy

Pharmaceutical Technology

JUNE 23, 2025

June 23, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook HBM7020 activates immune system T cells to target and destroy B cells and plasma cells involved in many autoimmune diseases. Credit: luchschenF /Shutterstock. Give your business an edge with our leading industry insights.

Communication

Communication Hospitals Packaging Insurance

MAXONA Pharma seeks FDA approval for pain relief MAX-001

Pharmaceutical Technology

AUGUST 8, 2025

Give your business an edge with our leading industry insights.

FDA

FDA Packaging Compounding Communication

EpiPen patent expiry opens new era for innovation

Pharmaceutical Technology

AUGUST 8, 2025

Give your business an edge with our leading industry insights.

Packaging

Packaging Communication Hospitals Insurance

FDA gives accelerated approval to Jazz Pharma’s diffuse midline glioma therapy

Pharmaceutical Technology

AUGUST 7, 2025

Give your business an edge with our leading industry insights.

FDA

FDA Adverse Reactions Packaging Labelling

Chugai and Gero link on antibody drugs for age-related conditions

Pharmaceutical Technology

JULY 8, 2025

Go deeper with GlobalData Reports LOA and PTSR Model - Briquilimab in Severe Combined Immune Deficien. Reports LOA and PTSR Model - Immune Globulin (Human) in Chronic Lymphocytic. Reports LOA and PTSR Model - Immune Globulin (Human) in Chronic Lymphocytic. Data Insights The gold standard of business intelligence.

Packaging

Packaging Immunization Hospitals Communication

Novo Nordisk signs $812m research deal with Deep Apple for non-GLP-1 drugs

Pharmaceutical Technology

JUNE 12, 2025

The biotech used these funds to establish a pipeline that includes three metabolic disease programmes, with further assets across immune disorders and endocrine diseases. Apple Tree Partners founded the Deep Apple in 2022, investing $52m in series A funding. Give your business an edge with our leading industry insights.

Compounding

Compounding Communication Hospitals Packaging

Kling Bio and Sanofi link for antibodies and epitopes discovery

Pharmaceutical Technology

JULY 24, 2025

It employs a function-first screening workflow to reveal rare and effective immune targets, thereby fast-tracking the next-generation prophylactics and treatments development. Kling-Select provides a powerful window into the human immune response and accelerates the identification of functional antibodies and novel epitopes.

Vaccines

Vaccines Packaging Communication Immunization

FDA Commissioner envisions fewer delays, more clinical trial flexibility and AI use

Pharmaceutical Technology

JUNE 18, 2025

fired 17 sitting members of the Advisory Committee on Immunization Practices at the Centers for Disease Control and Prevention (CDC), concerns rose about the stance of federal agencies on vaccines. Give your business an edge with our leading industry insights.

FDA

FDA Vaccines Communication Hospitals

FDA approves Takeda’s Gammagard liquid ERC for primary immunodeficiency

Pharmaceutical Technology

JULY 1, 2025

The US Food and Drug Administration (FDA) has approved Takeda’s new immunoglobulin (IG) therapy, Gammagard liquid ERC [immune globulin infusion (human)], to treat primary immunodeficiency (PI) in individuals aged two years and above. Credit: HenadziPechan/Shutterstock. Give your business an edge with our leading industry insights.

FDA

FDA Packaging Communication Hospitals

Sanofi to acquire Vicebio’s share capital for $1.15bn upfront

Pharmaceutical Technology

JULY 23, 2025

The technology stabilises viral proteins in their native shape, which may lead to more effective immune responses. Find out more Sanofi’s acquisition adds an early-stage combination vaccine for respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), as well as the Molecular Clamp technology.

Health and Personal Care Stores

Health and Personal Care Stores Vaccines Packaging Communication

Uncertainty looms over FDA scheme to boost US manufacturing

Pharmaceutical Technology

AUGUST 8, 2025

Give your business an edge with our leading industry insights.

FDA

FDA Packaging Communication Hospitals

Epkinly breaks ground in Phase III FL trial

Pharmaceutical Technology

AUGUST 8, 2025

Give your business an edge with our leading industry insights.

Packaging

Packaging FDA Communication Hospitals

NSW government invests $13.39m in life-changing therapies

Pharmaceutical Technology

JUNE 20, 2025

Find out more This treatment involves obtaining immune cells from patients, modifying them in a laboratory setting then reintroducing them into patients’ bodies to destroy cancerous cells. Data Insights The gold standard of business intelligence. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate?

Hospitals

Hospitals Communication Immunization Packaging

Regeneron nabs dosing edge with Lynozyfic’s FDA approval in multiple myeloma

Pharmaceutical Technology

JULY 3, 2025

It comes with one for cytokine release syndrome (CRS) and neurologic toxicity – including immune effector cell-associated neurotoxicity syndrome – in addition to warnings and precautions for infections, neutropenia, hepatotoxicity and embryo-foetal toxicity. Give your business an edge with our leading industry insights.

FDA

FDA Packaging Communication Hospitals

AbbVie buys $2.1bn Capstan, adding new in vivo CAR-T to pipeline

Pharmaceutical Technology

JULY 1, 2025

A preliminary look at the data from Capstan has revealed strong B-cell depletion – the aim of the treatment is to achieve an ‘immune reset’ by repopulation of healthy B cells. Investors shared positive sentiment in the acquisition, with shares in NYSE-listed AbbVie closing 1.7% higher at $185.62 on 30 June, the day the announcement was made.

Packaging

Packaging Communication Hospitals FDA

New US-EU trade deal on tariffs ends pharma’s geopolitical immunity

Pharmaceutical Technology

AUGUST 5, 2025

Companies manufacturing pharmaceutical products in Europe will need to anticipate financial exposure when planning launches in the US due to the unfavourable gross-to-net dynamics, weakened pricing leverage with US payers, and slower commercial uptake as insurers reassess cost-effectiveness due to the tariffs.

Immunization

Immunization Pharmaceutical Companies Pharmaceutical Companies Communication

CorMedix signs agreement to acquire Melinta for $300m

Pharmaceutical Technology

AUGUST 8, 2025

Give your business an edge with our leading industry insights.

Packaging

Packaging Hospitals Communication FDA

GSK eyes FDA label expansion for RSV vaccine Arexvy to include younger patients

Pharmaceutical Technology

JULY 14, 2025

A single dose of the vaccine in adults aged 18-49 at increased risk of RSV-LRTD elicited robust immune responses that were non-inferior to those observed in adults aged 60 and above. That is instead recommended by the US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP).

Labelling

Labelling Vaccines FDA Packaging

Gilead hit with FDA clinical hold for batch of HIV trials

Pharmaceutical Technology

JUNE 11, 2025

CD4+T-cells and lymphocytes are both crucial elements of the immune system. The FDA placed a hold on the trials due to the identification of a safety signal of decreases in CD4+T-cell (CD4) and absolute lymphocyte counts in a subset of participants receiving the GS-1720 and GS-4182 combination.

HIV Treatment and Prevention Agents

HIV Treatment and Prevention Agents FDA Communication Hospitals

Sino Biopharma spends $951m to acquire China-based LaNova Medicines

Pharmaceutical Technology

JULY 15, 2025

LaNova’s drug development focuses on tumour immunity and the tumour microenvironment. Sino revealed the acquisition agreement after trading hours on 15 July. The share price in the company had climbed 3.6% by market close. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate?

Packaging

Packaging Communication Hospitals Vaccines

EC approves BeOne’s Tevimbra for nasopharyngeal carcinoma

Pharmaceutical Technology

JULY 11, 2025

Its design minimises interaction with Fc-gamma (Fcγ) receptors on macrophages, enhancing the ability of the body’s immune cells to recognise and combat tumours. Give your business an edge with our leading industry insights.

Packaging

Packaging Hospitals Communication Labelling

FDA approves MSD’s Keytruda to treat head and neck cancer

Pharmaceutical Technology

JUNE 16, 2025

Keytruda is designed to enhance the immune system’s ability to detect and combat tumour cells. Based on these trial results, Keytruda as part of this regimen shows potential to change long-standing standards of care for treating certain patients with locally advanced HNSCC.” Give your business an edge with our leading industry insights.

FDA

FDA Research Laboratories Communication Hospitals

Astria Therapeutics licenses navenibart rights to Kaken for HAE

Pharmaceutical Technology

AUGUST 7, 2025

Kaken focuses its research and development on areas such as immune, nervous and infectious diseases, and on rare diseases with unmet medical needs. In 2023, Astria Therapeutics signed an exclusive global agreement to license Ichnos Sciences’ OX40 portfolio to treat AD. Sign up for our daily news round-up!

Packaging

Packaging Communication Immunization Hospitals

Brii Biosciences and Joincare sign licence agreement for BRII-693

Pharmaceutical Technology

JULY 4, 2025

Go deeper with GlobalData Reports LOA and PTSR Model - Briquilimab in Severe Combined Immune Deficien. Nominate Now Share Copy Link Share on X Share on Linkedin Share on Facebook Go deeper with GlobalData Reports LOA and PTSR Model - Briquilimab in Severe Combined Immune Deficien. Find out more Sign up for our daily news round-up!

Hospitals

Hospitals Packaging Communication Immunization

LEO Pharma secures rights to Boehringer’s Spevigo for $105m

Pharmaceutical Technology

JULY 15, 2025

LEO’s new asset is a monoclonal antibody that blocks the activation of the interleukin-36 (IL-36) receptor – a key signalling pathway in the immune system implicated in the pathogenesis of several autoinflammatory diseases. It has also been approved in expanded indications in GPP in certain territories.

Packaging

Packaging Communication Hospitals Vaccines

US instils 15% tariff rate on EU for pharmaceutical products

Pharmaceutical Technology

JULY 29, 2025

Neither the White House nor the EC responded to Pharmaceutical Technology when asked which generics would be immune to the agreement. Whilst the tariff rate is a blanket levy that applies to branded products, certain generic drugs will be exempt. Give your business an edge with our leading industry insights.

Packaging

Packaging Communication Hospitals Insurance

Mounjaro and Zepbound fuel strong Q2 growth for Eli Lilly

Pharmaceutical Technology

AUGUST 7, 2025

Give your business an edge with our leading industry insights.

Packaging

Packaging Communication Hospitals Insurance

Fresenius Kabi signs global licensing deal for Polpharma’s vedolizumab biosimilar

Pharmaceutical Technology

AUGUST 6, 2025

Give your business an edge with our leading industry insights.

Packaging

Packaging Communication Hospitals Vaccines

Moderna’s mRNA RSV vaccine wins expanded FDA approval for younger adults

Pharmaceutical Technology

JUNE 13, 2025

This approval was supported by results from Moderna’s Phase III study (NCT06067230), which demonstrated the vaccine’s immune response worked just as well in this age group compared to the existing approved age group of 60 years and older. The expanded approval now includes individuals aged 18 to 59 who are at risk of RSV.

Vaccines

Vaccines FDA Labelling Communication

Novo Nordisk files 14 new lawsuits against unapproved semaglutide drugs

Pharmaceutical Technology

AUGUST 6, 2025

Give your business an edge with our leading industry insights.

Compounding

Compounding Packaging FDA Communication

FDA removes Ixchiq partial pause but tightens vaccine’s use

Pharmaceutical Technology

AUGUST 8, 2025

The existing contraindication in individuals with weakened immune systems also remains. The agency states that most US travellers do not need to take Ixchiq due to the low risk of chikungunya exposure. Give your business an edge with our leading industry insights.

FDA

FDA Vaccines Packaging Communication

Novo Nordisk’s diabetes and weight loss drug sales growth decelerates

Pharmaceutical Technology

AUGUST 6, 2025

Give your business an edge with our leading industry insights.

Compounding

Compounding Packaging Communication Hospitals

RFK Jr’s mRNA funding halt signals “shift in US public health”

Pharmaceutical Technology

AUGUST 7, 2025

Give your business an edge with our leading industry insights.

Vaccines

Vaccines Packaging Communication Hospitals

RFK Jr axes vaccine advisory committee members

Pharmaceutical Technology

JUNE 10, 2025

The US department of Health and Human Services (HHS) has culled the 17 Biden-appointed members on the Advisory Committee for Immunization Practices (ACIP) at the Centers for Disease Control and Prevention (CDC) in a move observers warn is liable to further fuel the spread of vaccine-preventable illnesses. lev radin via Shutterstock.

Vaccines

Vaccines FDA Immunization Communication

Enterome to advance EO2463 immunotherapy with $19m funding

Pharmaceutical Technology

JUNE 12, 2025

By GlobalData Learn more about Strategic Intelligence By covering a wide range of targets on malignant B cells, the therapy aims to enhance safety and efficacy while minimising the potential of tumour cells for developing immune-resistance mechanisms such as antigen escape. Give your business an edge with our leading industry insights.

Communication

Communication Hospitals Packaging Insurance

Navigating uncertainty: the future of vaccine oversight amid CDC firings

Pharmaceutical Technology

JUNE 25, 2025

In a controversial move on 9 June 2025, US Secretary of Health and Human Services Robert F Kennedy Jr dismissed all 17 members of the Centers for Disease Control and Prevention (CDC) Advisory Committee for Immunization Practices (ACIP) that advises the federal government on vaccine safety.

Vaccines

Vaccines Packaging Hospitals Communication

How will RFK Jr’s American dream for vaccines play out?

Pharmaceutical Technology

JUNE 25, 2025

RFK Jr has flip-flopped between endorsing and shunning the MMR vaccine , a shot that is proven to provide strong immunity against the disease. Give your business an edge with our leading industry insights.

Vaccines

Vaccines Hospitals Packaging Communication

EHA 2025: AstraZeneca’s surovatamig is potential next-gen BiTE for R/R B-ALL

Pharmaceutical Technology

JUNE 16, 2025

A low incidence of immune effector cell-associated neurotoxicity syndrome was reported during the step-up dosing phase and the target dose phase. Two patients experienced dose-limiting toxicities and continued to receive the targeted dose. Give your business an edge with our leading industry insights.

Labelling

Labelling Communication Hospitals Vaccines

UK enacts law to decentralise manufacture of personalised treatments

Bharat Biotech acquires licence for GSK’s Shigella vaccine development

Trending Sources

MetrioPharm gains orphan drug status from EMA for MP1032

EC approves argenx’s efgartigimod alfa for CIDP treatment

Juvenescence enhances AI drug discovery with Ro5 acquisition

J&J seeks FDA approval for icotrokinra to treat psoriasis

Harbour BioMed partners Otsuka on new T-cell therapy

MAXONA Pharma seeks FDA approval for pain relief MAX-001

EpiPen patent expiry opens new era for innovation

FDA gives accelerated approval to Jazz Pharma’s diffuse midline glioma therapy

Chugai and Gero link on antibody drugs for age-related conditions

Novo Nordisk signs $812m research deal with Deep Apple for non-GLP-1 drugs

Kling Bio and Sanofi link for antibodies and epitopes discovery

FDA Commissioner envisions fewer delays, more clinical trial flexibility and AI use

FDA approves Takeda’s Gammagard liquid ERC for primary immunodeficiency

Sanofi to acquire Vicebio’s share capital for $1.15bn upfront

Uncertainty looms over FDA scheme to boost US manufacturing

Epkinly breaks ground in Phase III FL trial

NSW government invests $13.39m in life-changing therapies

Regeneron nabs dosing edge with Lynozyfic’s FDA approval in multiple myeloma

AbbVie buys $2.1bn Capstan, adding new in vivo CAR-T to pipeline

New US-EU trade deal on tariffs ends pharma’s geopolitical immunity

CorMedix signs agreement to acquire Melinta for $300m

GSK eyes FDA label expansion for RSV vaccine Arexvy to include younger patients

Gilead hit with FDA clinical hold for batch of HIV trials

Sino Biopharma spends $951m to acquire China-based LaNova Medicines

EC approves BeOne’s Tevimbra for nasopharyngeal carcinoma

FDA approves MSD’s Keytruda to treat head and neck cancer

Astria Therapeutics licenses navenibart rights to Kaken for HAE

Brii Biosciences and Joincare sign licence agreement for BRII-693

LEO Pharma secures rights to Boehringer’s Spevigo for $105m

US instils 15% tariff rate on EU for pharmaceutical products

Mounjaro and Zepbound fuel strong Q2 growth for Eli Lilly

Fresenius Kabi signs global licensing deal for Polpharma’s vedolizumab biosimilar

Moderna’s mRNA RSV vaccine wins expanded FDA approval for younger adults

Novo Nordisk files 14 new lawsuits against unapproved semaglutide drugs

FDA removes Ixchiq partial pause but tightens vaccine’s use

Novo Nordisk’s diabetes and weight loss drug sales growth decelerates

RFK Jr’s mRNA funding halt signals “shift in US public health”

RFK Jr axes vaccine advisory committee members

Enterome to advance EO2463 immunotherapy with $19m funding

Navigating uncertainty: the future of vaccine oversight amid CDC firings

How will RFK Jr’s American dream for vaccines play out?

EHA 2025: AstraZeneca’s surovatamig is potential next-gen BiTE for R/R B-ALL

Stay Connected